已收盘
0.000
NaN.00%
Sanofi weighs potential Insmed acquisition to offset Dupixent patent loss, prompting analysts to weigh respiratory synergy against deal cost and capacity.
今天 01:14
Insmed (INSM) stock surges over 18% after reports that French pharma giant Sanofi (SNY) is exploring a potential takeover.
11-20 02:57
https://www.bloomberg.com/news/articles/2026-11-19/sanofi-weighs-takeover-of-us-drugmaker-insmed
11-19 23:17
Agreement paves the way for newly diagnosed, transplant-ineligible patients fighting multiple myeloma to access first-line treatment Sarclisa® through provincial and territorial cancer treatment formulary listings.
11-16 22:16
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! (来源:凤凰WEEKLY财经) 11月5日至10日,第九届中国国际进口博览会在上...
11-10 16:31
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-16 22:46
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
10-03 01:19
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across
07-10 20:55